(2006; 14 pages)
The INN Programme was established by World Health Organization (WHO) to facilitate communication among health professionals in relation to pharmaceutical products used for therapeutic and prophylactic purposes. To serve this purpose, International Nonproprietary Names (INNs) are selected as single designations for individual pharmaceutical substances. As substances used in medicine and pharmacy are of highly diverse nature, individual classes of such substances require specific rules of nomenclature for creation of pertinent INNs.
Special situations mentioned above comprise creation of names of individual members belonging to a group of closely related substances. When the INN Programme was initiated, it was decided that in such situations, in order to limit the number of published INNs, an INN should be selected for one member of such a group only. This approach, which concerns especially substance sets formed by salts or esters of the same active moiety was validated in the 20th report of the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances (Technical Report Series No. 581). It has been left for the users of INNs (pharmacopoeia commissions, regulatory bodies, pharmaceutical manufacturers) to create the actual name of any individual substance that turns up in practical use, this to be done in conformity with the usual practice of naming chemical compounds. INNs created in this manner are referred to as INNMs (International Nonproprietary Names Modified).
Present review is addressed to those users of the INN system who have a need to create an INNM based on an existing INN...